Tonix Pharmaceuticals Holding short interest in 2018
In 2018, Tonix Pharmaceuticals Holding's disclosed short interest ran from 3.38% of shares outstanding on 12 Jan 2018 to 9.64% on 15 Nov 2018, a change of +6.26 percentage points. The year's high was 14.92% on 31 Oct 2018 and its low 2.03% on 13 Jul 2018, averaging 4.66% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.84 days on 28 Feb 2018. Full history: Tonix Pharmaceuticals Holding.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2025 · 2026
2018 in figures
- Start of year
- 3.38% (12 Jan 2018)
- End of year
- 9.64% (15 Nov 2018)
- Change
- +6.26 pp
- High
- 14.92% (31 Oct 2018)
- Low
- 2.03% (13 Jul 2018)
- Average
- 4.66%
- Highest days to cover
- 10.84 (28 Feb 2018)
- SEC filings marked
- 8
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 3.38% | 4.94 | |
| 31 Jan 2018 | 3.41% | 2.38 | |
| 15 Feb 2018 | 3.56% | 5.20 | |
| 28 Feb 2018 | 3.35% | 10.84 | |
| 15 Mar 2018 | 2.81% | 5.16 | 10-K filed, results (8-K) |
| 29 Mar 2018 | 2.93% | 3.87 | |
| 13 Apr 2018 | 2.82% | 2.89 | |
| 30 Apr 2018 | 2.51% | 3.52 | |
| 15 May 2018 | 2.90% | 1.98 | 10-Q filed, results (8-K) |
| 31 May 2018 | 2.52% | 3.27 | |
| 15 Jun 2018 | 2.72% | 1.00 | |
| 29 Jun 2018 | 2.83% | 1.17 | |
| 13 Jul 2018 | 2.03% | 1.05 | |
| 15 Aug 2018 | 2.17% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2018 | 5.41% | 1.00 | |
| 14 Sep 2018 | 4.96% | 1.44 | |
| 28 Sep 2018 | 6.11% | 2.13 | |
| 15 Oct 2018 | 12.29% | 1.00 | |
| 31 Oct 2018 | 14.92% | 1.00 | |
| 15 Nov 2018 | 9.64% | 1.21 | 10-Q filed, results (8-K) |
See also: Tonix Pharmaceuticals Holding's full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.